A cardiovascular trial asks more than a weight-loss trial
A lower number on a scale or an improved A1c does not by itself prove fewer heart attacks or strokes. SURPASS-CVOT directly studied cardiovascular outcomes, comparing tirzepatide with dulaglutide in adults with type 2 diabetes and atherosclerotic cardiovascular disease. I would start with that population and comparison before reading a claim about heart protection. The study is relevant evidence for a defined clinical setting. It is not a trial of every person interested in weight loss, every tirzepatide preparation or every commercial program offering access to treatment.[1]
The comparator was an active treatment, not placebo
Participants received weekly tirzepatide, up to 15 mg, or dulaglutide 1.5 mg. Dulaglutide was chosen as an active comparator with established cardiovascular evidence, not as an inert control. The sponsor’s trial registry identifies the study as NCT04255433 and describes a phase 3 cardiovascular comparison. This design matters because a medicine can meet a prespecified standard against another effective treatment without showing that it is better. A summary that quietly turns the comparator into no treatment changes the research question.[3]
What the published primary results showed
In the NEJM report, the primary composite outcome occurred in 801 participants, or 12.2%, assigned to tirzepatide and 862, or 13.1%, assigned to dulaglutide. The hazard ratio was 0.92, with a 95.3% confidence interval from 0.83 to 1.01. The analysis met the trial’s noninferiority criterion but did not meet statistical superiority for the primary endpoint. These are the publication’s figures. Keep their denominator and analysis together rather than substituting a slightly different product-label count into the same table.[1]
| Published measure | Result and comparison |
|---|---|
| Participants with a primary event | Tirzepatide: 801 (12.2%); dulaglutide: 862 (13.1%) |
| Hazard ratio, tirzepatide versus dulaglutide | 0.92 |
| 95.3% confidence interval | 0.83–1.01 |
| Primary testing conclusion | Noninferiority met; superiority not established |
NEJM publication analysis of cardiovascular death, myocardial infarction or stroke in adults with type 2 diabetes and atherosclerotic cardiovascular disease. Current label counts use a separately described population/analysis; figures should not be combined. Source: Nicholls et al.: SURPASS-CVOT cardiovascular outcomes, NEJM.
Noninferiority does not mean the treatments are identical
Noninferiority asks whether a result falls within a prespecified comparison margin. It does not prove that two treatments have identical effects for every person or outcome. Superiority asks a different question about evidence for a difference. Here, the primary confidence interval crossed the no-difference value of 1, so I would not describe the main result as proof that tirzepatide beat dulaglutide. The observed percentages can be stated, but the claim attached to them must preserve what the statistical testing established. For the difference between a relative comparison and event percentages, see absolute versus relative risk.
What the current Mounjaro indication says
The US Mounjaro prescribing information revised in August 2026 includes reducing major adverse cardiovascular events in adults with type 2 diabetes at high risk for these events. That label language is separate from the trial’s narrower enrolled population. It is also product-specific: the current Zepbound label and a compounded tirzepatide offer should not be presented as carrying the Mounjaro indication. An ingredient shared across offers does not make their regulatory status interchangeable. Ask the prescriber which approved product and indication apply to the proposed treatment.[2]
Do not merge SURPASS-CVOT with SELECT or SUMMIT
SELECT studied semaglutide in a different population and used a placebo comparison. SUMMIT addressed tirzepatide in obesity-related heart failure with preserved ejection fraction. Those studies can all inform cardiovascular research without becoming a single head-to-head ranking. Differences in baseline disease, comparator and endpoint prevent a clean comparison of headline percentages. I would make a small note beside each study identifying who entered and what counted as an event. That simple discipline is more useful than choosing the largest relative reduction from unrelated trials. For the separate semaglutide population, read our SELECT analysis. For the heart-failure question, see tirzepatide and SUMMIT.
Clinical eligibility and insurance coverage are separate decisions
An expanded indication does not automatically establish a person’s eligibility, a plan’s coverage or a practice’s ability to arrange treatment. The current product label is the starting point for a clinical discussion; the insurer still has its own benefit terms and any authorization requirements. Ask which product is being requested and what supporting information the plan needs. If a service quote assumes reimbursement, I would request the alternative cost if coverage is not obtained. Do not buy a membership on the assumption that the trial guarantees a particular insurance outcome.[4] Our LifeMD review examines the service arrangement, while the treatment and coverage decisions remain individualized.
What I would ask after reading the study
The useful appointment question is whether this evidence relates to your diabetes and cardiovascular history, and how it fits with the rest of your care. Ask what outcome the clinician is targeting, which product is being considered and how benefits and risks will be reviewed. If you then compare providers, keep product access, follow-up and the complete payment obligation visible. A cardiovascular outcomes paper does not rate the company selling the appointment. The strongest conclusion stays precise: this trial established noninferiority against dulaglutide on its primary cardiovascular comparison, with a current product label that must be read separately. Ask anyone presenting a cardiovascular claim to identify the medicine, the comparator and the outcome. If those details are missing, a promotional percentage is not yet enough information to assess how the evidence relates to you. Use our prior-authorization guide to organize the insurance questions once a clinician has identified the treatment.
Put the questions to work
Compare our researched providers or build your provider checklist.
Explore relevant provider reviews
Use these reviews to compare the published services and terms. Inclusion is a research starting point, not a recommendation for treatment.
Continue your research
Sources & scope
Sources checked October 23, 2026. This guide explains published information and consumer research questions; it is not a clinical evaluation.
- Nicholls et al.: SURPASS-CVOT cardiovascular outcomes, NEJM
- Lilly: current US Mounjaro prescribing information, revised August 2026
- Lilly trial registry: SURPASS-CVOT NCT04255433
- DailyMed: current Mounjaro product labeling
Prices and terms can change. Confirm your specific offer directly with the provider.